Note 17. Commitments and Contingencies

Rent expense for all leases for the years ended December 31, 2018, 2017 and 2016, was approximately $9.4 million, $8.2 million and $5.4 million, respectively.

Future non‑cancelable minimum payments are as follows (in thousands):


Year Ended December 31,	Operating Leases		Capital Leases		Financing Lease1
2019	$	12,909	$	688	$	—
2020		8,589		472		—
2021		3,899		—		466
2022		2,011		—		2,793
2023		1,155		—		2,793
Thereafter		—		—		35,850
Total minimum lease payments	$	28,563	$	1,160	$	41,902

1. Represents the future minimum lease payments relating to leases where we are deemed, for accounting purposes, to be the owner of the building (see Note 1 of the Notes to the Consolidated Financial Statements).

We lease approximately 112,000 square feet of office space in Chadds Ford, Pennsylvania, approximately 100,000 square feet of laboratory and office space in Wilmington, Delaware and approximately 63,000 square feet of office space in Europe and Japan.

In February 2018, we signed an agreement to rent a building in Morges, Switzerland for an initial term of 15 years, with multiple options to extend for an additional 20 years. The building will undergo extensive renovations prior to our occupation and, when completed, will serve as our new European headquarters. Once construction is complete, our future rental payments over the 15 year term are approximately $41.9 million, which excludes the remaining build-out costs to be paid by us.

We have entered into and may in the future seek to license additional rights relating to technologies or drug development candidates in connection with our drug discovery and development programs. Under these licenses, we may be required to pay upfront fees, milestone payments, and royalties on sales of future products, which are not reflected in the table above.

In December 2018, we received a civil investigative demand from the U.S. Department of Justice for documents and information relating to our speaker programs and patient assistance programs, including our support of non-profit organizations that provide financial assistance to eligible patients. We are cooperating with this inquiry. Given that the investigation is still ongoing and that we have not yet been made aware of the substance of any civil claims, we cannot predict the outcome of the investigation, the timing of the ultimate resolution of this matter, or reasonably estimate the possible range of loss, if any, that may result from this matter. Accordingly, no reserve has been made with respect to this matter in the 2018 consolidated financial statements.